|
1
|
Mellema WW, Burgers SA and Smit EF: Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: A case report. Lung Cancer. 87:201–203. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Blanchon F, Grivaux M, Asselain B, Lebas FX, Orlando JP, Piquet J and Zureik M: 4-year mortality in patients with non-small-cell lung cancer: Development and validation of a prognostic index. Lancet Oncol. 7:829–836. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
International Early Lung Cancer Action Program Investigators, . Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP and Miettinen OS: Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 355:1763–1771. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luczak MW and Jagodziński PP: The role of DNA methylation in cancer development. Folia Histochem Cytobiol. 44:143–154. 2006.PubMed/NCBI
|
|
6
|
Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A and MacLeod AR: DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet. 33:61–65. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Robertson KD: DNA methylation, methyltransferases, and cancer. Oncogene. 20:3139–3155. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin RK, Hsu HS, Chang JW, Chen CY, Chen JT and Wang YC: Alteration of DNA methyltransferases contributes to 5CpG methylation and poor prognosis in lung cancer. Lung Cancer. 55:205–213. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim H, Kwon YM, Kim JS, Han J, Shim YM, Park J and Kim DH: Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer. 107:1042–1049. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kramann R and Moeller MJ: The next level of complexity: Post-transcriptional regulation by microRNAs. Kidney Int. 80:692–693. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ambros V: The function of animal MicroRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang JY, Cheng H, Zhang HY, Ye YQ, Feng Q, Chen ZM, Zheng YL, Wu ZG, Wang B and Yao J: Suppressing microRNA-29c promotes biliary atresia-related fibrosis by targeting DNMT3A and DNMT3B. Cell Mol Biol Lett. 24:102019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Balkhi MY, Iwenofu OH, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ, London CA, Kraybill W, Perrotti D, Croce CM, et al: MiR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR. Sci Signal. 6:ra632013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, Zhao R, Huang H, Wang X, Qiao Y, et al: MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: A novel epigenetic therapy independent of decitabine. Oncogene. 33:378–386. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li L, Chen YY, Li SQ, Huang C and Qin YZ: Expression of miR-148/152 family as potential biomarkers in non-small-cell lung cancer. Med Sci Monit. 21:1155–1161. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Y, Huang S, Wei Z and Yang B: A putative competing endogenous RNA network in cisplatin-resistant lung adenocarcinoma cells identifying potentially rewarding research targets. Oncol Lett. 19:4040–4052. 2020.PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen Y, Min L, Ren C, Xu X, Yang J, Sun X, Wang T, Wang F, Sun C and Zhang X: MiRNA-148a serves as a prognostic factor and suppresses migration and invasion through Wnt1 in non-small cell lung cancer. PLoS One. 12:e01717512017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C and Liu Z: Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastriontest Surg. 14:1170–1179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng Z, Ma R, Tan W and Zhang L: MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2. Exp Mol Med. 46:e1122014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Su Y, Wang Y, Zhou H, Lei L and Xu L: MicroRNA-152 targets ADAM17 to suppress NSCLC progression. FEBS Lett. 588:1983–1988. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rutishauser U, Acheson A, Hall AK, Mann DM and Sunshine J: The neural cell adhesion molecule (NCAM) as a regulator of cell-cell interactions. Science. 240:53–57. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Crossland DL, Denning WL, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, Gold KS, Glisson BS, et al: Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene. 37:3686–3697. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Win KT, Lee MY, Tan TD, Tsai MP, Bahrami A, Raimondi SC and Chuang SS: Nasopharyngeal alveolar rhabdomyosarcoma expressing CD56: A mimicker of extranodal natural killer/T-cell lymphoma. Int J Clin Exp Pathol. 7:451–455. 2013.PubMed/NCBI
|
|
26
|
Amoureux MC, Coulibaly B, Chinot O, Loundou A, Metellus P, Rougon G and Figarella-Branger D: Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. BMC Cancer. 10:912010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aletsee-Ufrecht MC, Langley K, Rotsch M, Havemann K and Gratzl M: NCAM: A surface marker for human small cell lung cancer cells. FEBS Lett. 267:295–300. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Song T, Zhou H, Wei X, Meng Y and Guo Q: Downregulation of microRNA-324-3p inhibits lung cancer by blocking NCAM1-MAPK axis through ALX4. Cancer Gene Ther. 28:455–470. 2021. View Article : Google Scholar : PubMed/NCBI
|
